文献速递神经肿瘤

聚焦超声开放血脑屏障重塑胶质母细胞瘤患者血浆细胞外囊泡尺寸分布而不升高浓度

FUS-mediated BBB opening reshapes plasma extracellular vesicle size distribution without elevating concentration in glioblastoma patients.
PubMed 文献 · Neuro Oncol · 2026-07-14

该研究在胶质母细胞瘤患者中开展14例次MR引导聚焦超声血脑屏障开放,于超声前1小时和超声后1小时采血。结果显示血浆细胞外囊泡浓度无一致变化,但直径可重复性缩小约8-10 nm,主要源于尺寸分布上尾收缩;cfDNA浓度与片段化呈异质性。结论挑战了血脑屏障开放普遍增加生物标志物丰度的假设。

要点

  • 聚焦超声开放血脑屏障后细胞外囊泡浓度无一致升高,患者与操作间异质性明显。
  • 细胞外囊泡直径可重复性缩小约8-10 nm,主要来自较大囊泡亚群的收缩。
  • cfDNA浓度与片段化呈异质性,仅偶见患者特异性升高。

核心结论

  • 聚焦超声开放血脑屏障未一致增加血浆细胞外囊泡浓度,而是选择性调节其尺寸分布,提示并非简单提升生物标志物丰度。

研究设计与样本

  • 研究对胶质母细胞瘤患者实施14例次MR引导聚焦超声血脑屏障开放,超声前1小时与后1小时采血。
  • 血浆细胞外囊泡经尺寸排阻色谱分离,并用可调电阻脉冲传感技术定量;cfDNA用荧光法与电泳法评估。

主要发现

  • 细胞外囊泡浓度在血脑屏障开放后无一致变化,患者间与操作间异质性显著。
  • 细胞外囊泡直径呈可重复性缩小约8-10 nm,主要由尺寸分布上尾收缩驱动。
  • cfDNA浓度与片段化呈异质性模式,偶见患者特异性升高。
  • 探索性分析显示生物标志物变化与操作参数无显著关联,接受治疗体积除外。

临床怎么用

  • 血脑屏障开放后不宜假设细胞外囊泡总量必然升高,解读液体活检结果需考虑尺寸分布变化。
  • 细胞外囊泡在生理条件下可穿越血脑屏障,仍可作为神经肿瘤液体活检底物。

局限性

  • 探索性分析仅提示治疗体积与生物标志物变化相关,其余操作参数无显著关联。
  • 结果基于14例次操作,患者间与操作间异质性明显,需结合临床数据与机制模型进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Focused ultrasound-mediated blood-brain barrier opening (BBBO) is hypothesized to enhance liquid biopsy by facilitating the release of tumor material into the circulation. This study aimed to evaluate the impact of MR-guided FUS-BBBO on plasma extracellular vesicle (EV) concentrations and size distributions, alongside cell-free DNA (cfDNA) profiles, to determine the clinical efficacy of this approach in glioblastoma (GB) patients. METHODS: We performed 14 MR-guided focused ultrasound (FUS)-BBBO procedures in patients with GB with blood sampling 1 h before and 1 h after sonication. Plasma EVs were isolated by size-exclusion chromatography and quantified by tunable resistive pulse sensing technology. Cell-free DNA (cfDNA) concentration and fragment profiles were assessed using fluorometric and electrophoretic methods. RESULTS: EV concentration showed no consistent change after FUS-BBBO, with marked inter-patient and inter-procedure heterogeneity. In contrast, EV size displayed a reproducible diameter reduction of ∼8-10 nm, driven predominantly by contraction of the upper tail of the size distribution, indicating selective modulation of larger vesicle subpopulations. cfDNA concentrations and fragmentation showed a heterogeneous pattern, with occasional patient-specific increases. Exploratory analyses revealed no significant associations between biomarker changes and procedural parameters except for treated volume. CONCLUSIONS: Our findings challenge the assumption that clinical BBBO uniformly increases biomarker abundance. The consistent shift toward smaller EVs suggests a selective modulation rather than an increased release. While BBBO may enhance the detectability of analytes that poorly cross the BBB, this may not apply to EVs, which are able to traverse the BBB under physiological conditions, further supporting their value as liquid-biopsy substrates in neuro-oncology. Future studies integrating clinical data with mechanistic models are necessary to refine FUS-enhanced diagnostic strategies. This study evaluates whether opening the blood-brain barrier (BBB) using focused ultrasound (FUS) increases brain tumor biomarkers in the blood of glioblastoma patients. FUS did not uniformly increase total concentrations of extracellular vesicles (EVs) or cell-free DNA (cfDNA), showing highly variable patterns among patients. Instead, FUS consistently shifted the size distribution of EVs, causing a reproducible 8–10 nm downsizing by selectively affecting larger vesicles. These results challenge the assumption of a simple biomarker boost and suggest that patient-specific biology can play a major role in FUS-enhanced diagnostic strategies.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Del Bene M, Osti D, Bonada M, et al. FUS-mediated BBB opening reshapes plasma extracellular vesicle size distribution without elevating concentration in glioblastoma patients. Neuro Oncol. 2026. PMID: 42446136. doi:10.1093/neuonc/noag155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。